According to latest statement by Lifecare AS (LIFE-ME) announces it has enhanced its Board of Directors (BOD) after an extraordinary general meeting Friday 20 November 2020.
The Board of Directors is enhanced with members that have diabetes-, technology-, mergers and acquisition experience. The changes to the Board were in line with the recommendation from the company’s nomination committee and a proposal from the company’s largest shareholder Teigland Eiendom AS.
The new Board members are:
- Deputy chairman: Morten Foros Krohnstad, Bergen, Norway. Kronstad is a partner in the law firm Schjødt and has extensive experience as a business lawyer with main areas of work in M&A and corporate, including corporate litigation. He serves on a number of boards as chairman and board member in Norwegian listed and un-listed companies.
- Board member: Prof. Dr. Lutz Heinemann, Düsseldorf, Germany. Heinemann has a broad academic background with a special focus on research and development in insulin pharmacology and diabetes technology. Heinemann established the Profil Institute for Metabolic Research in Neuss, Germany in 2009 and since 2011 he has been Managing Editor of The Journal of Diabetes Science and Technology.
- Board member: Bo Petersson, Copenhagen, Denmark. Peterson holds a Ph.D. in Chemistry from The Technical University of Denmark. Peterson has over 20 years of work experience in developing diabetes technology products, most recently as Head of Diabetes Care at Cambridge Consultants, Cambridge, UK. Petersson is today also engaged as Chief Scientific Officer in RSP Systems A / S, Copenhagen, Denmark.
In addition to the newly elected Board members, the Board consists of Board chairman Christian Hysing-Dahl and Board member Trine Teigland. As previously announced, Joacim Holter leaves the board given his appointment as CEO.
“The Board of Lifecare is thus significantly strengthened and ready to continue the development and commercialization of diabetes technology, which is our main purpose. We are now looking forward to embarking on the further developments of Sencell to fulfill our aim to give people with diabetes the modern tool they deserve for monitoring glucose levels,” says the Chairman of the Board Christian Hysing-Dahl.